From Clarendon, Texas, USA:
My 13 year old daughter with diabetes was diagnosed with acanthosis nigricans under her arms and a slight amount of discoloration on her neck. She has had type 1 diabetes since she was six years old. Will you please explain the relationship between type 1 diabetes and acanthosis nigricans? Is this skin disorder related to insulin?
It would be very unusual, indeed, for Acanthosis Nigricans to be associated with autoimmune diabetes. The first question that arises is whether that diagnosis was correct. Six years ago, it is possible that she did not have an antibody test, which, if positive, would have confirmed the diagnosis of Typeá1A diabetes. Now, of course, it would be too late to do it.
This skin condition is not always associated with some form of diabetes, but, in your daughter's case, it would most likely to be linked to one of the many syndromes of insulin resistance. It would be relevant to know, for instance, if she was overweight, had any evidence of a raised blood pressure, whether there was a close family history of a similar problem and whether she seemed to have any evidence of increased muscularity. A C-peptide level that is elevated at this stage would strongly favour a diagnosis such as type A insulin resistance. You will need to discuss these possibilities with her doctor and perhaps ask for a specialist opinion.
Original posting 14 Sep 2000
Posted to Complications
|Return to the Top of This Page|
Last Updated: Tuesday April 06, 2010 15:09:14
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.